



2025

CORIELL INSTITUTE FOR MEDICAL RESEARCH
ANNUAL REPORT



CORIELL INSTITUTE
FOR MEDICAL RESEARCH



LETTER FROM

DR. JEAN-PIERRE ISSA

CORIELL PRESIDENT AND CEO



Dear Friends,

I am pleased to present our Annual Report for 2025, a truly momentous year for Coriell— in the lab, with our biobank, and for our future.

Our scientists' unrelenting, innovative research to identify the inherent genetic causes of cancer and other diseases was acknowledged with record funding from the National Institutes of Health (NIH).

Our world-renowned biobank was recognized once again for its scientific excellence and operational expertise with a prestigious new contract with the National Institute of Mental Health (NIMH) to manage its biospecimen and data collection, the "NIMH Repository and Genomics Resource," the largest centralized biorepository for psychiatric research with more than 3.5 million samples.

And, with much anticipation following years of planning, we broke ground for our new life sciences campus that will serve as our new headquarters, research center and biorepository, and house a state-designated Strategic Innovation Center for emerging biotech companies that we believe will make Camden a research destination.

Our successes are due to the outstanding team at Coriell, whose innovative theories, aspirations and imagination drive our pursuit to improve human health and be an anchor institution in the community.

Your devotion to your work and dedication to our mission is greatly appreciated.

I also want to thank our collaborators, donors, federal, state and local officials, the State of New Jersey, and community partners for your steadfast support of our work and aim to make Camden a life sciences research hub. We share our achievements with you and look forward to our ongoing collaborations for the benefit of patients and the residents of Camden.

Please enjoy this report and follow our research and progress on our new science campus on our social media. We are very excited about the innovative research we are conducting and the promise that our new facility holds for the Institute, patient care and the community.

Thank you for your interest in the Coriell Institute. Please contact us if you would like more information or to explore partnering with us.

JEAN-PIERRE ISSA, MD
PRESIDENT AND CHIEF EXECUTIVE OFFICER

CORIELL BOARD OF TRUSTEES

John Apathy, MBA
Arnaud Bastien, MD
Lou Bezich, MPP
Christopher R. Gibson, Esq.
Frank Giordano
Generosa Grana, MD, FACP
Matthew Hewitt, PhD

Robert Kiep, III, Chairman

Jean-Pierre Issa, MD
Marc S. Maser, Esq.
John Piccone
Annette C. Reboli, MD
Miruna Sasu, PhD
Roland Schwarting, MD
Kenneth A. Somberg, MD, MBA



BIOBANKING & RESEARCH

2025 was a monumental year for our globally recognized biobank. The year started strong with contract renewals with the National Institute on Aging (NIA) and the National Institute of General Medical Sciences (NIGMS) to continue to serve as their respective biospecimen repository, and a successful external ISO 9001:2015 audit. We also prevailed with proposals to the NIH to win a coveted grant and a prestigious new contract to host a sixth NIH collection.

Office of Research Infrastructure Programs (ORIP) Grant

The NIH's Office of Research Infrastructure Programs awarded Coriell a \$5 million grant to support the creation of a state-of-the-art Cell Engineering Center to be housed at Coriell's new headquarters. The center will be on the cutting edge of cell and developmental biology, serving as a core laboratory for NIH funded researchers across the country.



National Institute for Mental Health (NIMH)

The National Institute for Mental Health (NIMH) one of the 27 institutes and centers that comprise the National Institutes of Health (NIH) selected Coriell to manage its biospecimen and data collection, the "NIMH Repository and Genomics Resource (NRGR)," the largest centralized biorepository for psychiatric research. The resource currently contains more than 3.5 million samples from more than 200,000 individuals with psychiatric illness and neurotypical controls. The goal of the NRGR is to accelerate scientific understanding of the genetic and cellular bases of mental disorders and support translational neuroscience that will lead to new diagnostic tools, treatments, and preventative strategies for mental illness. This is a multi-year engagement valued at \$48,265,314 over the next five years.

2025 RESEARCH YEAR IN REVIEW

\$13,218,614

in total funding from Sponsored Research

50

*grants, contracts, and LOIs were processed
by the Coriell Research Office*

25

*research papers published by Coriell scientists
in leading research journals*



CORIELL POSTDOCTORAL RESEARCH

The Coriell Institute invites applications for postdoctoral research positions. Submit a CV and cover letter to HR@Coriell.org; Coriell HR will retain these resumes for 2 years, and will reach out to qualified candidates as positions open.

The Jean-Pierre Issa Lab

The Issa Lab investigates the many ways in which the epigenome plays a role in our health, from cancer development to the aging process. In studying epigenetics — how portions of our genome are activated and deactivated — the lab seeks to better understand how human health is impacted by and can potentially be improved with changes to the epigenome.

In 2025, the Issa Lab reported on a new study showing that molecular characteristics of colon cancer are sculpted by patient-specific microbiome features, potentially explaining patient to patient variability in clinical course and outcomes in this disease. Analyzing tumor samples from 203 colorectal cancer patients, the lab looked for high levels of four different bacteria and found that tumors with an especially high level of some of these bacteria are more likely to be CIMP-positive, a distinct cancer subtype that leads to the silencing of tumor suppressing genes.

For more information on the Issa Lab, [click here](#). Papers published by the lab in 2025 can be found in the list of Publications.

The Luke Chen Lab

The Chen Lab has multiple research interests in oral and esophageal cancers with a focus on cancer cell signaling and metabolism in esophageal squamous cell carcinoma (ESCC) with a translational intention.

In 2025, the Chen Lab received a two-year grant from the New Jersey Commission on Cancer Research (NJCCR), providing support for its research of nuclear factor erythroid 2-related factor 2 (NRF2), a master transcription factor that can become hyperactive in approximately 2% of human cancers, which can lead to poor clinical outcomes.

The W. W. Smith Charitable Trust also provided a grant to the Chen Lab, with a focus on targeting ACSS3, a major source of propionate in the gut microbiome.

For more information on the Chen Lab, [click here](#). Papers published by the lab in 2025 can be found in the list of Publications.

The Shumei Song Lab

The Song Lab is investigating cancer biology and molecular cancer biology, specifically in regard to gastrointestinal cancers. The lab has a further focus on upper gastrointestinal malignancies, including those found in the esophageal tract, the GE junction, and gastric cancer initiation, progression, therapy resistance and metastasis.

The Song group published seven papers as first, last, or co-author with three more manuscripts currently under review. Dr. Song was awarded a bridge grant from the New Jersey Commission on Cancer Research and has a R01 grant and a Department of Defense (DoD) Impact Award currently under review. Dr. Song and Dr. Zhang also submitted a patent application with Dr. Zhou and Dr. Jia at the University of Texas Medical Branch.

The lab presented two abstracts at the American Association for Cancer Research (AACR) Annual Meeting, and four additional abstracts were submitted to AACR 2026 and have all been accepted for presentation at the April 2026 meeting. Two abstracts were submitted to the Digestive Disease Week Annual Meeting. In addition, a research intern from the University of Delaware was accepted for training in the Song lab starting in January 2026.

For more information on the Song Lab, [click here](#). Papers published by the lab in 2025 can be found in the list of Publications.

The Nora Engel Lab

The Engel Lab studies the impact of the sex chromosomes on the transcriptional and epigenetic differences between males and females in melanoma progression and outcomes. The lab also investigates sex biases in the transcriptome and epigenome in melanocytes, the cell of origin of melanoma.

In 2025, the Engel Lab was awarded a new research grant from the W.W. Smith Charitable Trust. Externally, lab members presented at a variety of conferences, including the International Mammalian Genome Society and the American Physician Sciences Association Mid-Atlantic Regional Conference. Lab member Gillian McGuire, an MD/PhD candidate, received two first place awards for her conference presentations. The lab also welcomed a new post-doctoral fellow to the team.

For more information on the Engel Lab, [click here](#). Papers published by the lab in 2025 can be found in the list of Publications.

The Jian Huang Lab

The Huang Lab is investigating the regulation of hematopoietic stem cell (HSC) self-renewal and differentiation as well as drug resistance of hematological malignancies.

In 2025, the Huang Lab published sixteen papers as co-author or co-responding author and jointly filed one patent application. The lab received five new grants from the W.W. Smith Charitable Trust, New Jersey Commission on Cancer Research, and the National Heart, Lung, and Blood Institute.

For more information on the Huang Lab, [click here](#). Papers published by the lab in 2025 can be found in the list of Publications.

The Laura Scheinfeldt Lab

The Scheinfeldt Lab researches the ways in which human evolutionary history has shaped patterns of genetic and genomic variation across contemporary human populations, with a particular interest in variation that impacts health and disease.

In 2025, the Scheinfeldt Lab focused on a new Genetic Testing Reference Material (GeT-RM) Program resource for the identification of characterized DNA reference materials for pharmacogenetic and HLA testing. The project is part of an ongoing collaboration with the Genetic Testing Reference Materials Coordination Program led by Lisa Kalman at the Centers for Disease Control (CDC).

For more information on the Scheinfeldt Lab, [click here](#). Papers published by the lab in 2025 can be found in the list of Publications.

2025 NIH GRANTS

NAME	AWARDS	FUNDING
Luke Chen, MD, PhD	2	\$1,197,162
Jian Huang, MD, PhD	3	\$1,031,478
Jean-Pierre Issa, MD	1	\$2,521,916
Laura Scheinfeldt, PhD	1	\$864,373
Shumei Song, MD, PhD	1	\$884,176
Nahid Turan, PhD	2	\$6,719,509
TOTAL	10	\$13,218,614

2025 PUBLICATIONS

The PI3K pathway is a downstream effector of NRF2 activation in the esophagus.

Subramaniam B, Li Y, Xiong Z, Paiboonrungruang C, Bui-Linh C, Spitz F, Chen X.

Translational Oncology. 2025 Dec 3.

Whole-genome sequencing reveals individual and cohort level insights into chromosome 9p syndromes.

Wang Y, Sams EI, Slaugh R, Crocker S, Hurtado EC, Tracy S, Hou YC, Markovic C, Valle K, Tate V, Belhassan K, Appelbaum E, Akinwe T, Starosta RT, Cao Y, Neilson A, Liu Y, Jensen N, Ghasemi R, Lindsay T, Manuel J, Couteranis S, Kremitzki M, Ustanik J, Antonacci T, Ng JK, Emory A, Metz L, DeLuca T, Lyons KN, Sinnwell T, Thomeczek B, Wang K, Sisneros N, Muraleedharan M, Kethireddy A, Corbo M, Gowda H, King KA, Gurnett CA, Dutcher SK, Gooch C, Li YE, Mitchell MW, Peterson KA, Horani A, Rosenfeld JA, Bi W, Stankiewicz P, Chao HT, Posey JE, Grochowski CM, Dardas Z, Puffenberger EG, Pearson CE, Kooy F, Annear D, Innes AM, Heinz M, Head R, Fulton R, Toutain S; 9P-ARCH; Antonacci-Fulton L, Cui X, Mitra RD, Cole FS, Neidich J, Dickson PI, Milbrandt J, Turner TN.

Genome Medicine. 2025 Oct 24;17(1):129.

Pyrimethamine and a potent analog inhibit NRF2 by suppressing one-carbon metabolism.

Chembo J, Bowman BM, Lapak K, Wilkerson E, Wamsley NT, Paiboonrungruang C, Cho K, Medcalf MR, Wang H, Patti GJ, Dolle RE, Chen X, Zolkind P, Major MB.

Journal of Biological Chemistry 2025 Oct;301(10):110659.

Recurrent structural variation and recent turnover at the 17q21.31 locus in humans and great apes.

Sridharan S, Lou RN, Ferguson S, Rocha JL, De-Kayne R, Mitchell MW, Killilia AN, Borda V, Medina-Munoz SG, Gravel S; CAAPA2 PopGen Working Group; Henn B, Sudmant PH.

bioRxiv. 2025 Sep 23:2025.08.15.670618.

A complete diploid human genome benchmark for personalized genomics.

Hansen NF, Dwarshuis N, Ji HJ, Rhie A, Loucks H, Logsdon GA, Vollger MR, Storer JM, Kim J, Adam E, Altemose N, Antipov D, Asri M, Barreira S, Bohaczuk SC, Bzikadze AV, Carioscia SA, Carroll A, Chao KH, Chu Y, Das A, Ebert P, English A, Fleharty M, Fleming LE, Formenti G, Guarracino A, Hartley GA, Jenike K, Kalleberg J, Kang Y, King R, Lipovac J, Mastoras M, Mitchell MW, Negi S, Olson ND, Oshima KK, Paulin LF, Pickett BD, Porubsky D, Ranchalis J, Ranjan D, Rautiainen M, Riethman H, Schnabel RD, Sedlazeck FJ, Shafin K, Sikic M, Solar SJ, Sweeten AP, Timp W, Wagner J, Yoo D, Zhou Y, Garrison E, Eichler EE, Schatz MC, Stergachis AB, O'Neill RJ, Miga KH, Salzberg SL, Koren S, Zook JM, Phillippy AM.

bioRxiv. 2025 Sep 21:2025.09.21.677443.

New Resources to Identify Characterized DNA Reference Materials for Pharmacogenetic (PGx) and Human Leukocyte Antigen (HLA) Testing: The Genetic Testing Reference Material (GeT-RM) Program PGx Search Tool and GeT-RM Consolidated PGx and HLA Table

Scheinfeldt L, Kusic D, Gaedigk A, Turner AJ, Moyer AM, Pratt VM, Kalman LV.

Journal of Molecular Diagnostics. 2025 Jun;27(6):457-464.

New iPSC resource with long-read whole genome sequencing characterizations for enhanced in vitro modeling.

Scheinfeldt L, Pompetti A, Calendo G, Pozner T, Grandizio C, Smith G, Hodges K, Gharani N, Kusic D, Mitchell MW, Turan N.

bioRxiv. 2025 Jun 21:2025.06.17.660113

IN NEED OF
CORE FACILITIES?



[Learn more at Coriell.org](https://www.coriell.org)

ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer.

Stojanovic L, Abbotts R, Tripathi K, Coon CM, Rajendran S, Abbasi Farid E, Hostetter G, Guarnieri JW, Wallace DC, Liu S, Wan J, Calendo G, Marker R, Gohari Z, Inayatullah MMA, Tiwari VK, Kader T, Santagata S, Drapkin R, Kommos S, Pfisterer J, Konecny GE, Coopergard R, Issa JJ, Winterhoff BJN, Topper MJ, Sandusky GE, Miller KD, Baylin SB, Nephew KP, Rassool FV.
Cancer Research. 2025 Apr 3;85(7):1183-1198.

Metabolic flux analysis in hiPSC-CMs reveals insights into cardiac dysfunction in propionic acidemia.

Richard E, Marchuk H, Álvarez M, He W, Chen X, Desviat LR, Zhang GF.
Cellular and Molecular Life Sciences. 2025 Apr 2;82(1):137.

ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination.

Li H, Chatla S, Liu X, Tian Z, Vekariya U, Wang P, Kim D, Octaviani S, Lian Z, Morton G, Feng Z, Yang D, Sullivan-Reed K, Childers W, Yu X, Chitralla KN, Madzo J, Skorski T, Huang J.

Cancer Letter. 2025 Mar 31;613:217505.

Elevated propionate and its association with neurological dysfunctions in propionic acidemia.

Chen X, Cheng Q, Zhang GF.
Frontiers in Molecular Neuroscience. 2025 Mar 19;18:1499376. eCollection 2025.

HSP90 inhibitor AUY922 suppresses tumor growth and modulates immune response through YAP1-TEAD pathway inhibition in gastric cancer.

Yoshimura K, Zou G, Fan Y, Yamashita K, Wang L, Wu J, Wang R, Shao S, Scott AW, Jin J, Pizzi MP, Yao X, Brown CA, Wang L, Gan Q, Waters RE, Yin F, Song S, Dhar SS, Ajani JA.
Cancer Letter. 2025 Feb 1; 610:217354.

YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases.

Wu J, Athavale D, Balch C, Zhao J, Zou G, Fan Y, Zhang Y, Zhao J, Ghelfi M, Pompetti A, Calendo G, Scott A, Shao S, Yao X, Pizzi MP, Vellano C, Khazak V, Zhang S, Yap TA, Dhar SS, Sundar R, Spitz F, Grana G, Ajani JA, Song S.
bioRxiv [Preprint]. 2025 Nov 14:2025.11.13.683933.

A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML.

Kropf PL, Chung W, Shameem R, Xiao L, Balch C, Huang X, Issa JJ.
Blood Neoplasia. 2025 Jan 23;2(2):100071.

Exosomal Galectin-3 promotes peritoneal metastases in gastric adenocarcinoma via microenvironment alterations.

Fan Y, Song S, Pizzi MP, Zou G, Vykoukal JV, Yoshimura K, Jin J, Calin GA, Waters RE, Gan Q, Wang L, Hanash S, Dhar SS, Ajani JA.
iScience. eCollection 2025 Jan 17.

Human iPSC Reprogramming Success: The Impact of Approaches and Source Materials.

Pozner T, Grandizio C, Mitchell MW, Turan N, Scheinfeldt L.
Stem Cells International. 2025 Jan 16;2025:2223645.

Engraftment of a surrogate antigen onto tumor cell surface via pHILIP peptide to universally target CART cell therapy to solid tumors.

Zhang YT, Fu X, Ting Lim JJ, Zhang SX.
Cancer Letter. 2025 Jan 1;608:217319.

Complete genomes of a multi-generational pedigree to expand studies of genetic and epigenetic inheritance.

Cechova M, Potapova TA, Rechtsteiner A, Hickey G, Mari RS, Mastoras M, Menendez J, Poláková N, Hebbar P, Ryabov F, Loucks H, Groot A, Pavlík T, Asri M, Dong S, Yan SM, Lucas JK, Solar SJ, Borchers M, Mattingly M, McKinney S, Krátká M, Mikhailova C, Hanák O, Saha ST, Xu E, Antipov D, Koren S, Eizenga JM, McNulty B, Gardner JMV, Hillaker T, Violich I, Markovic C, Kruglyak S, Levy S, Wolf T, Mitchell MW, Scheinfeldt L, Cheng H, Alexandrov IA, McCoy RC, Paten B, Phillippy AM, Zook JM, Gerton JL, Fulton RS, Stitzel NO, Wang T, Marschall T, Greider CW, Miga KH.
bioRxiv. 2025 Dec 16:2025.12.14.693655.

Adipose-Derived Stem Cells Prevent Anastomotic Leak: A Porcine Ischemic Esophagectomy Model.

Williams J, Knapp K, Zilberman B, Lin A, Verchio V, Antonello Z, Zhang P, DeLong D, Spitz F, Barroeta JE, Chen X, Shersher D.
Journal of Surgical Research, Volume 305, 2025, Pages 65-79.

Evolution of Esophageal Adenocarcinoma From Precursor Lesion Stem Cells.

Xian W, Wang S, Xie J, Yamamoto Y, Khorrami M, Zhang Y, Montes RC, Desales C, Khorrami M, Mory Z, Hoffman A, Su A, Nguyen C, Davies PJA, Stephan C, Pan S, Wu W, Liu Y, Siegelman J, Waters RE, Ross WA, Song S, Metersky M, Beer DG, Crum CP, Stewart AJ, Vincent M, Russell R, Izard RA, Ho KY, Hung-Sen Lai J, Bachovchin WW, Ajani JA, McKeon FD.

Gastroenterology. 2025 Aug;169(2):277-293.e4. doi: 10.1053/j.gastro.2025.02.032. Epub 2025 Mar 14.

Mitochondrial quality control in hematopoietic stem cells: mechanisms, implications, and therapeutic opportunities.

Liao Y, Octaviani S, Tian Z, Wang SR, Huang C, Huang J. **Stem Cell Research & Therapy.** 2025 Apr 15;16(1):180.

DNA Methylation, Aging, and Cancer.

Vaidya H, Jelinek J, Issa JJ. **Epigenomes.** 2025 Jun 3;9(2):18.

KAP1 promotes gastric adenocarcinoma progression by activating Hippo/YAP1 signaling via binding to HNRNPAB.

Song S, Fan Y, Zou G, Huo L, Kumar J, Li Y, Wang R, Dai E, Jin J, Scott AW, Shao S, Pizzi MP, Vykoukal JV, Katayama H, Hanash S, Calin GA, Zhang X, Lee MG, Wang Z, Lo YH, Gan Q, Waters RE, Yin F, Wang L, Cheng X, Ajani JA, Dhar SS.

Cancer Lett. 2025 Jul 1;621:217695. doi: 10.1016/j.canlet.2025.217695. Epub 2025 Apr 4

Protocol for isolating patient-derived ascites cells and extracellular vesicles from gastric cancer peritoneal metastases.

Fan Y, Vykoukal JV, Song S, Pizzi MP, Zou G, Yoshimura K, Jin J, Katayama H, Calin GA, Waters RE, Gan Q, Wang L, Hanash S, Dhar SS, Ajani JA.

STAR Protocols. 2025 Oct 16;6(4):104133.

Lymphatic Metastasis of Esophageal Squamous Cell Carcinoma: The Role of NRF2 and Therapeutic Strategies.

Li Y, Ladd Z, Xiong Z, Bui-Linh C, Paiboonrungruang C, Subramaniyan B, Li H, Wang H, Balch C, Shersher DD, Spitz F, Chen X.

Cancers (Basel). 2025 May 31;17(11):1853.



As part of our pledge to communicate and collaborate with the international scientific community, Coriell's scientists and staff routinely contribute their findings to leading publications. To see our latest findings, check our website.



COMMUNITY CONNECTIONS

STEM EDUCATION

44th Annual Science Fair

More than 100 middle and high school students from Burlington, Camden and Gloucester counties competed in the 44th Annual Coriell Science Fair, held at Rutgers University — Camden. The fair provides a platform for STEM-minded students to showcase their passion for science through their exceptional projects. 67 students, across the fair's 14 STEM categories, advanced to the Delaware Valley Regional Science Fair, where 27 of them won honors. We hope that our annual science fair is a rewarding experience that will jump-start a life-long, rewarding scientific career.



Annual Summer Experience

Our Summer Experience for high school and college students is another of our highly valued programs to provide students with hands-on experience to enhance their interest in biomedical research. In 2025, twelve students had the opportunity to be a member of our research and production teams, spending time in each of our cell culture, stem cell, and molecular biology labs and biobank.

We hope that our summer interns will return to Coriell upon completion of their college studies to continue their education in our post-doctoral program, assisting our scientists with their innovative research.



CORIELL IN THE NEWS



Coriell Institute will build new Camden sciences campus to support biobanking, biotech efforts



44th Annual Coriell Science Fair Story



Coriell Institute Breaks Ground on New HQ and Strategic Innovation Center



\$95M biotech center is turning N.J. city into a life sciences powerhouse



Coriell Institute is moving its HQ. Why its big plans have the attention of Gov. Murphy



Coriell Institute breaks ground on new life sciences campus and strategic innovation center in Camden

New campus to house NIH Biobanks and 45,000-SF Biotech incubator and add 100 permanent jobs as Camden prepares for 2028 opening



NJEDA, Coriell Institute for Medical Research Announce New Innovation Center in Camden



Coriell Institute breaks ground on new innovation center in Camden, New Jersey



South Jersey's Expanding Spirit of Entrepreneurialism


New Jersey's lower eight counties are awash in entrepreneurial endeavors, and select nonprofit entities are encouraging such activity.



Coriell Institute begins work on \$95M innovation center and HQ in Camden

CORIELL WELCOMES STATE LEADERS

Coriell was honored to host Governor Phil Murphy, First Lady Tammy Murphy, our legislative representatives, the leadership of the New Jersey Economic Development Authority and New Jersey Commission on Science, Innovation and Technology and representatives from Sen. Andy Kim's office in 2025, to discuss our expanding research programs, plans for the future, and vision for building a life sciences innovation ecosystem in southern New Jersey.



Left to right: Coriell Board Chair Robert Kiep, Dr. Jean-Pierre Issa, President and CEO, Governor Phil Murphy, First Lady Tammy Murphy

Left to right: Dr. Jean-Pierre Issa, Assemblywoman Melinda Kane, Senator James Beach



Left to right: Assemblyman William Moen, Dr. Jean-Pierre Issa, Senator Nilsa Cruz-Perez, Assemblyman William Spearman



PARTNER IN THE COMMUNITY

Being an active member of the Camden community was a foundational tenet of our founder, Dr. Lewis L. Coriell, when he established the Institute in 1953.

The Coriell Institute is proud to continue Dr. Coriell's credo through partnerships with our neighboring institutions and community organizations to benefit the residents and patients of Camden, including the Parkside Business and Community in Partnership, Camden Community Partnership, Cooper Hospital Foundation, Cooper Medical School at Rowan University, and MD Anderson.




Cooper Medical School
of Rowan University



Cooper
Foundation

THE UNIVERSITY OF TEXAS
MD Anderson
Cancer Center

Making Cancer History®





THE FUTURE



GROUNDBREAKING FOR NEW SCIENCE CAMPUS

Joined by Governor Phil Murphy, Congressman Donald Norcross, Camden City Mayor Vic Carstarphen, Camden County legislators and commissioners, Camden City Council members, and community partners, we reaffirmed our founder Dr. Lewis Coriell's commitment to the City of Camden and the scientific community with a groundbreaking for our long-planned science campus in the Parkside neighborhood of the city.

For 73 years, Coriell has stood at the forefront of scientific discovery and been a proud anchor institution in the City of Camden and cornerstone of South Jersey's life sciences sector. Leveraging our standing in the scientific community and expertise in research and biobanking, we expect this project to be the catalyst to build a life sciences ecosystem in the region and make Camden a life sciences research destination.

This first building will serve as our new headquarters, research center, and biorepository, which will include housing six NIH biobanks.

The top two floors of this four-story building will house the NJ Coriell Labs Innovation Center, a joint project of the Coriell Institute and the NJEDA, that will encompass 45,000 square feet of premium incubator space to host emerging biotechnology companies. The NJ Coriell Labs Innovation Center will also provide access to core facilities, a vivarium and corporate suites, as well as to Coriell's renowned biobanking and laboratory services, making it a one-stop shop for a developing biotech company's infrastructure and laboratory needs. Companies will also have the ability to collaborate with Coriell scientists, the Camden Cancer Research Center and other leading research and healthcare institutions in the region.

The building is expected to open in 2028 and generate a multitude of permanent jobs.

GIVING

For more than 70 years, the Coriell Institute has been breaking new ground in biomedical research, and we are not slowing down but setting the bar higher.

Our successes are due to the strong support we receive from leading public and private entities that share our vision to improve human health, such as the National Institutes of Health, the State of New Jersey, private disease foundations, fellow academic research institutions and in particular, individuals who share in our vision

Thanks to the generosity of our donors who share our goal of fostering a longer, healthier, and high quality of life, we are able to conduct research that is constantly expanding the boundaries of biomedical science.

To make a contribution, or if you would like further information, please contact us at giving@coriell.org or visit coriell.org/donation.



Facts Figures

130

Employees

10,500

*Diseases represented
in our biobank*

\$13M

*for ten competitive NIH awards
in FY25*

99

Countries supplied by Coriell

1,007

*New diseases added to
our collection*

Get the latest updates. Connect with the Coriell Institute.

CoriellInstitute



@Coriell_Science



@CoriellInstitute



@coriellinstitute.bsky.social



@CoriellInstitute



coriell.org

